Bivamelagon (LB54640)

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals has established itself as a leader in the niche but high-value market of rare genetic diseases of obesity, successfully transitioning from a clinical-stage developer to a commercial entity with its flagship product, IMCIVREE®. The company's strategy is anchored in a deep scientific focus on the melanocortin-4 receptor (MC4R) pathway, supported by one of the largest genetic databases for severe obesity, enabling targeted drug discovery and development. Recent regulatory successes, including FDA approval for acquired hypothalamic obesity and a positive CHMP opinion in the EU, underscore its execution capability and expand its addressable patient population. Rhythm's forward strategy involves broadening IMCIVREE's label, advancing a diversified pipeline of next-generation candidates, and leveraging its genetic testing initiatives to diagnose and treat a growing spectrum of MC4R pathway diseases.

Therapeutic Areas

Other Acquired Hypothalamic Obesity Drugs